Indivior PLC (NASDAQ:INDV - Get Free Report) shares hit a new 52-week high on Friday . The company traded as high as $15.58 and last traded at $16.09, with a volume of 2981689 shares changing hands. The stock had previously closed at $15.40.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on INDV shares. Wall Street Zen raised shares of Indivior from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Piper Sandler decreased their price target on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a research note on Thursday, March 6th. Finally, Craig Hallum increased their price objective on Indivior from $15.00 to $22.00 and gave the stock a "buy" rating in a research note on Monday. Three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $17.00.
Read Our Latest Stock Analysis on Indivior
Indivior Stock Up 4.4%
The stock's 50 day moving average is $12.70 and its two-hundred day moving average is $11.24.
Indivior (NASDAQ:INDV - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.22 by $0.19. Indivior had a negative net margin of 4.02% and a negative return on equity of 97.29%. The business had revenue of $266.00 million during the quarter, compared to analyst estimates of $240.13 million. As a group, analysts anticipate that Indivior PLC will post 1.22 EPS for the current year.
Hedge Funds Weigh In On Indivior
A number of large investors have recently bought and sold shares of INDV. GF Fund Management CO. LTD. purchased a new stake in Indivior during the fourth quarter worth $36,000. Lazard Asset Management LLC bought a new position in shares of Indivior in the 4th quarter worth $57,000. Schaper Benz & Wise Investment Counsel Inc. WI purchased a new stake in shares of Indivior during the 1st quarter worth $95,000. Cannon Global Investment Management LLC bought a new stake in Indivior during the first quarter valued at about $95,000. Finally, CTC Alternative Strategies Ltd. bought a new stake in Indivior during the first quarter valued at about $96,000. Institutional investors own 60.33% of the company's stock.
Indivior Company Profile
(
Get Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
See Also
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
